Table 1 Correlation between CENPF expression and clinicopathological features in gliomas
From: CENPF interaction with PLA2G4A promotes glioma growth by modulating mTORC1 and NF-κB pathways
Clinicopathological Parameter, value | CENPF expression | ||||||
|---|---|---|---|---|---|---|---|
N | Low expression | High expression | χ2 value | P value | |||
Gender | |||||||
Male | 33 (55.0) | 14 (42.4) | 19 (57.6) | ||||
Female | 27 (45.0) | 14 (52.0) | 13 (48.0) | 0.530 | 0.466 | ||
Age | |||||||
<49 | 29 (48.3) | 15 (51.7) | 14 (48.3) | ||||
≥49 | 31 (51.7) | 13 (41.9) | 18 (58.1) | 0.577 | 0.447 | ||
Tumor location | |||||||
Frontal | 38 (63.3) | 16 (42.1) | 22 (57.9) | ||||
Temporal | 15 (25.0) | 10 (66.7) | 5 (33.3) | ||||
Other | 7 (11.7) | 2 (28.6) | 5 (71.4) | 3.649 | 0.161 | ||
WHO grade | |||||||
I-II | 22 (36.7) | 16 (72.3) | 6 (27.7) | ||||
III-IV | 38 (63.3) | 12 (31.6) | 26 (68.4) | 9.479 | 0.002* | ||
MGMT expression | |||||||
Low expression | 42 (70.0) | 21 (50.0) | 21 (50.0) | ||||
High expression | 18 (30.0) | 7 (38.9) | 11 (61.1) | 0.625 | 0.429 | ||
P53 status | |||||||
Wild | 33 (55.0) | 20 (60.6) | 13 (39.4) | ||||
Mutation | 27 (45.0) | 8 (29.7) | 19 (70.3) | 5.725 | 0.016* | ||
Ki-67 expression | |||||||
Low expression | 35 (58.3) | 24 (68.6) | 11 (31.4) | ||||
High expression | 25 (41.7) | 4 (16.0) | 21 (84.0) | 16.194 | 0.001* | ||